Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7
Original Research
![Noteworthy comment: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. The objective of this study was to examine the impact on the ICER of the future introduction of lower cost generic versions of the a new patented drug (NPRx) within the model’s time horizon. ICER estimated within economic evaluations comparing NPRx to generic comparators which ignore the future introduction of lower cost generic versions of the NPRx within the model’s time horizon will tend to be overestimated. Inclusion of this parameter should be considered within future economic evaluations.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
16,380 | Dovepress* | 15,708+ | 1,416 | 17,124 | |
PubMed Central* | 672 | 305 | 977 | ||
Totals | 16,380 | 1,721 | 18,101 | ||
*Since 6 October 2015 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
10 | 0 | 0 | 0 | 5 | 5 |
View citations on PubMed Central and Google Scholar